Traws Pharma, Inc. - Common (TRAW) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2024 to Q3 2025

Type / Class
Equity / Common
Symbol
TRAW on Nasdaq
Shares outstanding
7,989,235
Price per share
$1.23
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
1,304,595
Total reported value
$2,413,244
% of total 13F portfolios
0%
Share change
+41,108
Value change
+$101,966
Number of holders
18
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Traws Pharma, Inc. - Common (TRAW) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PERCEPTIVE ADVISORS LLC 10% 0% $1,676,216 +$645,794 886,887 +63% Perceptive Advisors LLC 30 Sep 2025
ORBIMED ADVISORS LLC 20% $1,498,823 760,824 ORBIMED ADVISORS LLC 31 Dec 2024
Squadron Capital Management LLC 8.4% +40% $1,116,990 +$322,243 591,000 +41% Squadron Capital Management LLC 30 Sep 2025
Ikarian Capital, LLC 10% 0% $1,161,319 +$384,637 589,502 +50% Ikarian Capital, LLC 31 Mar 2025
Chernett Jorey 6.8% $668,220 543,268 Chernett Jorey 14 Jan 2026
Ayrton Capital LLC 9.9% $795,190 403,650 Ayrton Capital LLC 31 Dec 2024
Adage Capital Management, L.P. 4.7% -26% $623,700 330,000 0% Adage Capital Management, L.P. 30 Sep 2025
Alyeska Investment Group, L.P. 9.9% $595,436 302,252 Alyeska Investment Group, L.P. 31 Dec 2024

As of 30 Sep 2025, 18 institutional investors reported holding 1,304,595 shares of Traws Pharma, Inc. - Common (TRAW). This represents 16% of the company’s total 7,989,235 outstanding shares.

Top 22 Institutional Shareholders

The largest institutional shareholders of Traws Pharma, Inc. - Common (TRAW) together control 16% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 7.6% 605,531 0% 0.03% $1,120,232
ADAGE CAPITAL PARTNERS GP, L.L.C. 4.1% 330,000 0% 0% $610,500
Vestal Point Capital, LP 1.9% 150,000 +0.13% 0.01% $277,500
VANGUARD GROUP INC 1.1% 87,259 +562% 0% $161,429
GEODE CAPITAL MANAGEMENT, LLC 0.54% 43,440 +22% 0% $80,366
Ikarian Capital, LLC 0.36% 28,493 0% 0.01% $52,712
TWO SIGMA INVESTMENTS, LP 0.28% 22,018 +37% 0% $40,733
HRT FINANCIAL LP 0.16% 12,573 0% $23,000
XTX Topco Ltd 0.13% 10,708 0% $19,810
BlackRock, Inc. 0.12% 9,956 0% 0% $18,419
CITIGROUP INC 0.04% 3,528 +5780% 0% $6,527
MORGAN STANLEY 0.01% 719 0% 0% $1,330
SBI Securities Co., Ltd. 0% 162 0% 0% $300
BANK OF AMERICA CORP /DE/ 0% 102 +8.5% 0% $189
Vermillion & White Wealth Management Group, LLC 0% 96 0% 0% $178
UBS Group AG 0% 6 -100% 0% $11
FMR LLC 0% 2 0% 0% $4
ASSETMARK, INC 0% 2 0% $4
Tower Research Capital LLC (TRC) 0% 0 -100% $0
TWO SIGMA SECURITIES, LLC 0% 0 -100% $0
Alyeska Investment Group, L.P. 0% 0 -100% $0
RAYMOND JAMES FINANCIAL INC 0% 0 -100% $0

Institutional Holders of Traws Pharma, Inc. - Common (TRAW) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 1,304,595 $2,413,244 +$101,966 $1.85 18
2025 Q2 1,263,487 $1,869,962 -$1,075,286 $1.48 19
2025 Q1 1,732,309 $3,984,315 +$1,207,344 $2.30 18
2024 Q4 1,141,975 $10,140,752 +$4,400,866 $8.88 17
2024 Q3 646,356 $3,800,574 +$3,742,032 $5.88 10